ClinicalTrials.gg
CompletedNCT01440374ASPIREUpdated Jun 5, 2017Results posted

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

A Phase 2 interventional study of eltrombopag and placebo in Thrombocytopaenia, sponsored by Novartis Pharmaceuticals. Completed at 120 sites in 22 countries. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2017-06-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing eltrombopag in Thrombocytopenia — 2 open to participants now, 3 under way, none of them phase 3. eltrombopag · Thrombocytopenia.

Enrollment
8th of 53
162 · median 40
Started
2011
with 5 others
Phase 2
27 of 53
2 open now
Registered
27th of 53
by date
Lead sponsor
6 of 53
Novartis Pharmaceuticals

Among the 53 studies testing eltrombopag in Thrombocytopenia, this one is the 8th largest by enrollment, is one of 6 that started in 2011, is one of 27 in phase 2, and was the 27th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

2 of the 53 studies testing eltrombopag in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing eltrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

This was a worldwide, three-part (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension), multi-center study to evaluate the effect of eltrombopag in subjects with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who have thrombocytopenia due to bone marrow insufficiency from their underlying disease or prior chemotherapy. This objective was assessed by a composite primary endpoint that consists of the following: the proportion of ≥Grade 3 hemorrhagic adverse events, or platelet counts \<10 Gi/L, or platelet transfusions. Patients with MDS or AML and Grade 4 thrombocytopenia due to bone marrow insufficiency from their underlying disease or prior chemotherapy were enrolled in the study. No low or intermediate-1 risk MDS subjects were enrolled in the study. Subjects must have had at least one of the following during the 4 weeks prior to enrolment: platelet count \<10 Gi/L, platelet transfusion, or symptomatic hemorrhagic event. Supportive standard of care (SOC), including hydroxyurea, was allowed as indicated by local practice throughout the study. The study had 3 sequential parts. Subjects who were enrolled in Part 1 (open-label) cannot be enrolled in Part 2 of the study (randomized, double-blind); however, subjects who completed the treatment period for Part 1 or Part 2 (8 and 12 weeks, respectively) continued in Part 3 (extension) if the investigator determined that the subject was receiving clinical benefit on treatment.

03

Conditions studied

  • Thrombocytopaenia

Keywords

  • acute myeloid leukemia (AML)
  • acute myelogenous leukemia (AML)
  • acute non lymphocytic leukemia (ANLL)
  • myeloproliferative disease (MDS)
  • myelodysplastic syndrome ( secondary acute myeloid leukemia)
  • refractory acute myeloid leukemia
04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects (18 years of age or older) with MDS or AML (bone marrow blasts ≤50%) with thrombocytopenia due to bone marrow insufficiency from the disease or prior treatment. Subjects with transient thrombocytopenia due to active treatment with disease modifying agents or chemotherapy (except for hydroxyurea) are excluded.
  • Subjects must have Grade 4 thrombocytopenia ( counts \<25 Gi/L) due to bone marrow insufficiency (or Grade 4 thrombocytopenia, but platelet count greater than or equal to 25 Gi/L due to platelet transfusion). In addition, subjects must have had at least one of the following during the 4 week screening period: platelet transfusion, or symptomatic bleeding or platelet count \<10 Gi/L. Subjects whose thrombocytopenia below 10 Gi/L is due to causes other than bone marrow insufficiency (e.g., fever, infection, disease) are not eligible.
  • Subjects must have platelet count, bleeding and platelet transfusion data available over a period of at least 4 weeks prior to randomization.
  • Prior systemic treatment for , with the exception of hydroxyurea, must have been discontinued prior to entry into the study: at least 4 weeks before Day 1 for the following: chemotherapy, demethylating agents (azacitidine or decitabine), lenalidomide, thalidomide, clofarabine and IL-11(oprelvekin); at least 8 weeks before Day 1 for antithymocyte/antilymphocyte globulin.
  • Subjects with a prior stem cell transplant (SCT) must have after the SCT.
  • Subjects must be stable and, in the opinion of the investigator, be expected to complete a 12 week treatment period.
  • Status 0-2.
  • Subject must be able to understand and comply with protocol requirements and instructions.
  • Subject has signed and dated an form.
  • Adequate baseline organ function defined by the criteria below: total ≤ 1.5xULN except for Gilbert's syndrome or cases clearly not indicative of inadequate liver function (i.e. elevation of indirect (hemolytic) bilirubin in the absence of abnormality), ALT ≤ 3xULN, creatinine ≤ 2.5xULN
  • Women must be either of non-child bearing potential or women with and men with must be willing to practice acceptable methods of during the study Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to the first dose of study treatment.
  • In France, a subject eligible for inclusion in this study only if either affiliated to, or a beneficiary of, a social security category.

Exclusion criteria

Exclusion Criteria:

  • Subjects with MDS and an IPSS of low or intermediate-1 risk at screening.
  • Subjects with a diagnosis of acute promyelocytic or megakaryocytic leukemia or AML secondary to a myeloproliferative neoplasm.
  • History of treatment with romiplostim or other TPO-R agonists.
  • Subjects with a >480 msec (QTc >510 msec for subjects with Bundle Branch Block).
  • Leukocytosis ≥25,000/uL on Day 1 of treatment with study medication.
  • Subjects with known thrombophilic risk factors. Exception: Subjects for whom the potential benefits of participating in the study outweigh the potential risks of thromboembolic events, as determined by the investigator.
  • Female subjects who are nursing or pregnant (positive serum or urine β-human chorionic gonadotropin [β-hCG] pregnancy test) at screening or pre-dose on Day 1.
  • Current alcohol or drug abuse.
  • Treatment with an drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
  • Active and uncontrolled infections (e.g. sepsis, , ).
  • Subjects infected with (HIV).
  • Subjects with liver cirrhosis (as determined by the investigator).
  • Subjects receiving or planned to receive any prohibited medication.
  • Have a known immediate or delayed reaction or idiosyncrasy to drugs chemically related to eltrombopag or (microcrystalline cellulose, mannitol, polyvinylpyrrolidone, sodium starch glycolate, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol 400 and polysorbate 80) that contraindicates the subjects' participation.
  • In France, subjects who have participated in any study using an investigational drug during the previous 30 days.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Part 1, Open Label

    100 mg daily (50 mg for subjects of East Asian heritage), intrasubject dose escalations to a maximum dose 300 mg (150 mg for subjects of East Asian heritage) are allowed.

    Drug: eltrombopag

  • Experimental
    Part 2, eltrombopag arm

    100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)

    Drug: eltrombopag

  • Experimental
    Part 2, placebo arm

    100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)

    Drug: placebo

  • Experimental
    part 3 extension

    100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)

    Drug: eltrombopag

Interventions

  • 100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)

    Also known as: Promacta

  • Drugplacebo

    100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Platelet Response up to Week 8 During Part 1

    A participant was considered as a responder if he/she met the following response criteria: a Baseline platelet count \<20 Giga cells per liter (Gi/L) and a post-Baseline increased to \>20 Gi/L and at least 2 times the Baseline value; or a Baseline platelet count \>=20 Gi/L and a post-Baseline absolute platelet count increased to \>=50 Gi/L and at least 2 times the Baseline value. The response criteria was evaluated at each visit. Increase in platelet count observed up to 3 days after a platelet transfusion was not considered as a platelet response. The Part 1 Population was comprised of all participants enrolled into Part 1.

    Time frame: From Baseline up to Week 8 during Part 1

  2. Clinically Relevant Thrombocytopenic Events (CRTE) From Week 5 up to Week 12 During Part 2

    A participant was considered to have a CRTE at a given assessment if he/she had platelet counts \<10 Gi/L, or platelet transfusions, or \>=Grade 3 hemorrhagic adverse events. CRTEs during Weeks 5 to 12 were compared between treatments using a generalized linear mixed model. Average of weekly proportion of subjects with CRTE during Week 5 to 12 was estimated for each treatment. Intent to Treat (ITT) Population was comprised of all randomized participants during Part 2.

    Time frame: From Week 5 up to Week 12 during Part 2

Secondary outcomes

  1. Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 1 Subjects)

    Time frame: Day 1 to week 8

  2. Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 2 Subjects)

    Time frame: Day 1 to week 12

  3. Mean Number of Platelet Transfusions

    Time frame: Weeks 5 to 12

  4. Hematologic Improvement

    Definitions of hematologic improvement for platelets, neutrophils, and hemoglobin were based on modified International Working Group (IWG) consensus criteria.

    Time frame: Weeks 5 to 12

  5. Change in Mean Platelet Count

    Time frame: Baseline to Week 12

  6. Maximum Duration of Platelet Transfusion Independence

    Time frame: Weeks 5 to 12

  7. Number of Participants With Maximum Bleeding Grade According to World Health Organization on Bleeding Scale

    Occurrence and severity of bleeding, measured using the WHO Bleeding Scale Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross blood loss; Grade 4=debilitating blood loss.

    Time frame: Weeks 5 to 12

  8. Independent Reviewer-Assessed Best Response

    Participants were evaluated in accordance with the modified International Working Group (Cheson, 2006). CR: Bone marrow blasts \<5%, Hgb ≥11g/dL, Hematologic Improvement - Platelets (Baseline \<20Gi/L: \>20 Gi/L and 2x baseline; Baseline ≥20 Gi/L: ≥50 Gi/L and 2x baseline), Neutrophils ≥1.0 Gi/L, Peripheral blasts 0%. PR: Bone marrow blasts decreased by ≥50% but \>5%, Peripheral blood as in CR. Marrow CR: Bone marrow blasts \<5% and decrease by ≥50%, Note any Hematologic Improvements, Stable disease: Failure to achieve PR, but no evidence of progression for \>8w, Cytogenetic response: Complete: disappearance of chromosomal abnormality; no new abnormalities Partial: ≥50% reduction of chromosomal abnormality.

    Time frame: up to week 12

  9. Independent Reviewer Assessed Disease Progression

    Time frame: Up to week 12

  10. Median Overall Survival

    Time frame: Up to 13 months

  11. Summary of Health Outcomes

    The number of subject with medical resource utilization (MRU) data are reported in this table. MRU included number of emergency room visits, number of home healthcare visits, number of hospitalization days, number of medication or surgery specialist visits, number of procedures inpatient, number of procedures outpatient, number of non-study radiology visits, number of non-study laboratory visits, number of nurse practitioner/physician assistance/nurse visits, number of primary care physician visits, number of telephone consultations.

    Time frame: week 12

  12. Functional Assessment of Cancer Therapy (FACT)

    The FACT-Th-18 is the most widely used and accepted tool evaluating health-related quality-of-life outcomes in cancer patients with chronically low platelets (where Th designates thrombocytopenia). The entire FACT-Th-18 was used in this trial, which includes the 18-item thrombocytopenia subscale used to assess the impact of symptoms, signs, and functional consequences of thrombocytopenia in MDS and AML subjects. The FACT-Th-18 is a validated and reliable instrument with known psychometric properties. FACT-ThS is an 18 item questionnaire specific to assessing the impact of symptoms, signs, and functional consequences of Thrombocytopenia. ThS score ranges from 0 to 72 with higher the score, the better the QoL. FACT G total score moves from 0 to 108 where higher the score, the better the HRQL. FACT-Th Total Score is calculated by adding the FACT-ThS and FACT-G score. Total score ranges from 0 to 180 and again, higher the score, the better the HRQL.

    Time frame: Change from baseline, up to week 12

  13. EQ-5D Utility Score Analysis

    EuroQoL Five Dimensions Questionnaire (EQ-5D) is a standardized generic preference based health related quality of life instrument. It records how one's health is "today" and consists of a descriptive system. The Descriptive system is Comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem(s) and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life. EQ-ED is a score.

    Time frame: Change from baseline, up to week 12

07

Results

Posted Jun 14, 2016

Participant flow

Part 1, 17 subjects received open-label eltrombopag. Part 2, 145 subjects were randomized to receive eltrombopag plus SOC (N=98) or placebo plus SOC (N=47). Part 3, 59 subjects from Part 2 entered Part 3. SOC was allowed as needed throughout the study. Subjects could receive disease-modifying therapy as needed.

Part 1: Open-label Phase
Participant flow — Part 1: Open-label Phase
MilestonePart 1: EltrombopagPart 2: PlaceboPart 2: EltrombopagPart 3: Eltrombopag
Started17000
Completed11000
Not completed6000
Withdrew: Adverse event5000
Withdrew: Physician decision1000
Part 2; Double-blind Phase
Participant flow — Part 2; Double-blind Phase
MilestonePart 1: EltrombopagPart 2: PlaceboPart 2: EltrombopagPart 3: Eltrombopag
Started047980
Completed027430
Not completed020550
Withdrew: Physician decision08170
Withdrew: Withdrawal by subject0450
Withdrew: Protocol violation0010
Withdrew: Lack of efficacy0100
Withdrew: Adverse event07310
Withdrew: Not treated0010
Part 3: Extension
Participant flow — Part 3: Extension
MilestonePart 1: EltrombopagPart 2: PlaceboPart 2: EltrombopagPart 3: Eltrombopag
Started00059
Completed00027
Not completed00032
Withdrew: Withdrawal by subject0005
Withdrew: Adverse event00013
Withdrew: Physician decision00014

Outcome measures

PrimaryNumber of Participants With Platelet Response up to Week 8 During Part 1

A participant was considered as a responder if he/she met the following response criteria: a Baseline platelet count \<20 Giga cells per liter (Gi/L) and a post-Baseline increased to \>20 Gi/L and at least 2 times the Baseline value; or a Baseline platelet count \>=20 Gi/L and a post-Baseline absolute platelet count increased to \>=50 Gi/L and at least 2 times the Baseline value. The response criteria was evaluated at each visit. Increase in platelet count observed up to 3 days after a platelet transfusion was not considered as a platelet response. The Part 1 Population was comprised of all participants enrolled into Part 1.

Time frame:
From Baseline up to Week 8 during Part 1
Reported as:
Number · Participants
Number of Participants With Platelet Response up to Week 8 During Part 1
ParticipantsPart 1: Eltrombopag
Number of Participants With Platelet Response up to Week 8 During Part 14
PrimaryClinically Relevant Thrombocytopenic Events (CRTE) From Week 5 up to Week 12 During Part 2

A participant was considered to have a CRTE at a given assessment if he/she had platelet counts \<10 Gi/L, or platelet transfusions, or \>=Grade 3 hemorrhagic adverse events. CRTEs during Weeks 5 to 12 were compared between treatments using a generalized linear mixed model. Average of weekly proportion of subjects with CRTE during Week 5 to 12 was estimated for each treatment. Intent to Treat (ITT) Population was comprised of all randomized participants during Part 2.

Time frame:
From Week 5 up to Week 12 during Part 2
Reported as:
Mean · percentages of participants
Clinically Relevant Thrombocytopenic Events (CRTE) From Week 5 up to Week 12 During Part 2
percentages of participantsPart 2: PlaceboPart 2: Eltrombopag
Clinically Relevant Thrombocytopenic Events (CRTE) From Week 5 up to Week 12 During Part 269 (57 to 80)54 (43 to 64)
Statistical analysis
  • Part 2: Placebo vs Part 2: Eltrombopag · Generalized Linear Mixed Models · p = 0.0315 · Odds ratio (or): 0.202 · 95% CI 0.047 to 0.868
SecondaryPlasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 1 Subjects)
Time frame:
Day 1 to week 8
Reported as:
Mean · ug/mL
Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 1 Subjects)
ug/mLPart 1: Eltrombopag
Baseline/day 1 (Pre-dose PK)0 ± 0
Day8 week 1 (Pre-dose PK)7.7 ± 3.96
Day15 week 2 (Pre-dose PK)7.2 ± 5.17
Day22 week 3 (Pre-dose PK)14.3 ± 10.63
Day29 week 3 (2-6hrs post-dose PK)20.8 ± 14.98
Day36 week 5 (Pre-dose PK)20.2 ± 16.37
Day43 week6 (2-6hrs post-dose PK)41.2 ± 32.56
Day50 week 7 (Pre-dose PK)30.4 ± 27.95
Day57 week 8 (2-6hrs post-dose PK)30.1 ± 18.99
SecondaryPlasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 2 Subjects)
Time frame:
Day 1 to week 12
Reported as:
Mean · ug/mL
Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 2 Subjects)
ug/mLPart 2: Eltrombopag
Baseline/day 1 (Pre-dose PK)0 ± 0
Day15 week 2 (Pre-dose PK)10.1 ± 5.54
Day22 week 3 (2-6hrs post-dose PK)24.0 ± 14.6
Day29 week 4 (Pre-dose PK)20.2 ± 13.61
Day43 week 6 (Pre-dose PK)29.0 ± 18.13
Day50 week 7 (2-6hrs post-dose PK)42.9 ± 22.37
Day57 week8 (Pre-dose PK)36.3 ± 20.91
Day71 week 10 (Pre-dose PK)33.5 ± 20.40
Day78 week 11 (2-6hrs post-dose PK)41.2 ± 24.91
Day85 week12 (Pre-dose PK)30.7 ± 18.03
SecondaryMean Number of Platelet Transfusions
Time frame:
Weeks 5 to 12
Reported as:
Mean · Number of platelet transfusions
Mean Number of Platelet Transfusions
Number of platelet transfusionsPart 2: EltrombopagPart 2: Placebo
Mean Number of Platelet Transfusions18.8 ± 18.6015.7 ± 20.36
SecondaryHematologic Improvement

Definitions of hematologic improvement for platelets, neutrophils, and hemoglobin were based on modified International Working Group (IWG) consensus criteria.

Time frame:
Weeks 5 to 12
Reported as:
Number · Number of subjects
Hematologic Improvement
Number of subjectsPart 2: EltrombopagPart 2: Placebo
Any Improvement104
Platelets82
Neutrophils44
Hemoglobin00
Platelets and neutrophils22
Platelets and hemoglobin00
Platelets, hemoglobin and neutrophils00
Neutrophils and hemoglobin00
SecondaryChange in Mean Platelet Count
Time frame:
Baseline to Week 12
Reported as:
Mean · Gi/L
Change in Mean Platelet Count
Gi/LPart 2: EltrombopagPart 2: Placebo
Day8 week13.36 ± 11.7951.66 ± 6.249
Day15 week210.41 ± 60.2253.06 ± 9.675
Day22 week36.23 ± 22.8722.13 ± 9.258
Day29 week45.63 ± 17.5822.44 ± 11.215
Day36 week58.58 ± 22.5045.9 ± 16.000
Day43 week68.64 ± 19.7795.93 ± 21.960
Day50 week79.91 ± 25.5616.74 ± 31.074
Day57 week89.67 ± 23.2437.84 ± 34.213
Day64 week912.84 ± 27.2726.75 ± 31.709
Day71 week1015.97 ± 33.8666.23 ± 30.941
Day78 week1114.42 ± 36.9016.92 ± 26.906
Day 85 week129.06 ± 28.2594.85 ± 26.219
SecondaryMaximum Duration of Platelet Transfusion Independence
Time frame:
Weeks 5 to 12
Reported as:
Mean · maximum duration of platelet transfusion
Maximum Duration of Platelet Transfusion Independence
maximum duration of platelet transfusionPart 2: EltrombopagPart 2: Placebo
Maximum Duration of Platelet Transfusion Independence26.3 ± 21.4725.4 ± 19.70
SecondaryNumber of Participants With Maximum Bleeding Grade According to World Health Organization on Bleeding Scale

Occurrence and severity of bleeding, measured using the WHO Bleeding Scale Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross blood loss; Grade 4=debilitating blood loss.

Time frame:
Weeks 5 to 12
Reported as:
Number · Number of subjects
Number of Participants With Maximum Bleeding Grade According to World Health Organization on Bleeding Scale
Number of subjectsPart 2: EltrombopagPart 2: Placebo
Grade 0 (no bleeding)154
Grade 1 (petechiae)3122
Grade 2 (mild blood loss)4114
Grade 3 (gross blood loss)53
Grade 4 (debilitating blood loss)13
Grades 0 - 14626
Grades 1 - 47842
Grades 2 - 44720
SecondaryIndependent Reviewer-Assessed Best Response

Participants were evaluated in accordance with the modified International Working Group (Cheson, 2006). CR: Bone marrow blasts \<5%, Hgb ≥11g/dL, Hematologic Improvement - Platelets (Baseline \<20Gi/L: \>20 Gi/L and 2x baseline; Baseline ≥20 Gi/L: ≥50 Gi/L and 2x baseline), Neutrophils ≥1.0 Gi/L, Peripheral blasts 0%. PR: Bone marrow blasts decreased by ≥50% but \>5%, Peripheral blood as in CR. Marrow CR: Bone marrow blasts \<5% and decrease by ≥50%, Note any Hematologic Improvements, Stable disease: Failure to achieve PR, but no evidence of progression for \>8w, Cytogenetic response: Complete: disappearance of chromosomal abnormality; no new abnormalities Partial: ≥50% reduction of chromosomal abnormality.

Time frame:
up to week 12
Reported as:
Number · Number of subjects
Independent Reviewer-Assessed Best Response
Number of subjectsPart 2: EltrombopagPart 2: Placebo
Responder11
Complete response (CR)00
Morphologic CR01
Morphologic leukemia-free state00
Marrow CR10
Cytogenetic CR00
Molecular CR00
Non-responder9746
Partial response00
Stable disease (non-responder)1810
Progressive disease (non-responder)4128
Not evaluable (non-responder)368
Missing (non-responder)20
SecondaryIndependent Reviewer Assessed Disease Progression
Time frame:
Up to week 12
Reported as:
Number · Number of subjects
Independent Reviewer Assessed Disease Progression
Number of subjectsPart 2: EltrombopagPart 2: Placebo
Disease progression61 ± 21.4736 ± 19.70
No disease progression126
Not evaluable235
Missing20
SecondaryMedian Overall Survival
Time frame:
Up to 13 months
Reported as:
Median · Months
Median Overall Survival
MonthsPart 2: EltrombopagPart 2: Placebo
Median Overall Survival4.27 (2.96 to 7.59)4.6 (3.29 to 7.82)
SecondarySummary of Health Outcomes

The number of subject with medical resource utilization (MRU) data are reported in this table. MRU included number of emergency room visits, number of home healthcare visits, number of hospitalization days, number of medication or surgery specialist visits, number of procedures inpatient, number of procedures outpatient, number of non-study radiology visits, number of non-study laboratory visits, number of nurse practitioner/physician assistance/nurse visits, number of primary care physician visits, number of telephone consultations.

Time frame:
week 12
Reported as:
Number · Subject with Events
Summary of Health Outcomes
Subject with EventsPart 2: EltrombopagPart 2: Placebo
Number of emergency room visits (n=17, n=10)10
Number of home healthcare visits (n=17, n=10)21
Number of hospitalization days (n=17, n=10)54
Number of med/surg specialist visits (n=17, n=10)13
Number of procedures inpatient (n=17, n=10)21
Number of procedures outpatient (n=17, n=10)11
Number of non-study radiology visits (n=2, n=2)22
Number of nurse prac/pa/nurse visits (n=17, n=10)53
Number of primary care physician visits (n=17,10)71
Number of telephone consultations (n=17, n=10)10
Number of non-study laboratory visits (n=17, n=10)86
SecondaryFunctional Assessment of Cancer Therapy (FACT)

The FACT-Th-18 is the most widely used and accepted tool evaluating health-related quality-of-life outcomes in cancer patients with chronically low platelets (where Th designates thrombocytopenia). The entire FACT-Th-18 was used in this trial, which includes the 18-item thrombocytopenia subscale used to assess the impact of symptoms, signs, and functional consequences of thrombocytopenia in MDS and AML subjects. The FACT-Th-18 is a validated and reliable instrument with known psychometric properties. FACT-ThS is an 18 item questionnaire specific to assessing the impact of symptoms, signs, and functional consequences of Thrombocytopenia. ThS score ranges from 0 to 72 with higher the score, the better the QoL. FACT G total score moves from 0 to 108 where higher the score, the better the HRQL. FACT-Th Total Score is calculated by adding the FACT-ThS and FACT-G score. Total score ranges from 0 to 180 and again, higher the score, the better the HRQL.

Time frame:
Change from baseline, up to week 12
Reported as:
Mean · Adjusted mean change from baseline
Functional Assessment of Cancer Therapy (FACT)
Adjusted mean change from baselinePart 2: EltrombopagPart 2: Placebo
FACTG week 5 (n=61. n=34)-0.79 ± 1.64-3.15 ± 2.19
FACTG week 9 (n=46. n=28)-4.83 ± 1.82-2.76 ± 2.34
FACTG week12 (n=37. n=26)-3.38 ± 1.94-4.17 ± 2.39
FACTHTOI week 5 (n=61, n=34)0.91 ± 2.04-2.28 ± 2.74
FACTHTOI week 9 (n=46, n=28)-1.69 ± 2.240.19 ± 2.89
FACTHTOI week 12 (n=37, n=26)-0.26 ± 2.37-1.56 ± 2.95
SecondaryEQ-5D Utility Score Analysis

EuroQoL Five Dimensions Questionnaire (EQ-5D) is a standardized generic preference based health related quality of life instrument. It records how one's health is "today" and consists of a descriptive system. The Descriptive system is Comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem(s) and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life. EQ-ED is a score.

Time frame:
Change from baseline, up to week 12
Reported as:
Mean · Adjusted mean change from baseline
EQ-5D Utility Score Analysis
Adjusted mean change from baselinePart 2: EltrombopagPart 2: Placebo
Week 5 (n=55. n=34)-0.01 ± 0.04-0.15 ± 0.05
Week 9 (n=43. n=27)-0.08 ± 0.04-0.06 ± 0.05
Week 12 (n=36. n=26)-0.09 ± 0.05-0.11 ± 0.05

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag, Part 1 Subjects—9/17 (52.9%)17/17 (100%)
Eltrombopag, Part 2 Plus 1 Day From Part 2 Subjects—56/97 (57.7%)89/97 (91.8%)
Placebo, Part 2 Plus 1 Day From Part 2 Subjects—32/47 (68.1%)44/47 (93.6%)
Eltrombopag, Part 3 Plus 30 Days From Part 2 Subjects—39/59 (66.1%)54/59 (91.5%)
Most frequent serious events
Showing 10 of 125
Most frequent serious events
EventEltrombopag, Part 1 SubjectsEltrombopag, Part 2 Plus 1 Day From Part 2 SubjectsPlacebo, Part 2 Plus 1 Day From Part 2 SubjectsEltrombopag, Part 3 Plus 30 Days From Part 2 Subjects
SepsisInfections and infestations4/178/975/476/59
PneumoniaInfections and infestations1/1714/975/4710/59
Febrile neutropeniaBlood and lymphatic system disorders0/177/977/476/59
PyrexiaGeneral disorders2/177/976/477/59
Septic shockInfections and infestations2/171/971/473/59
Urinary tract infectionInfections and infestations0/173/971/475/59
BronchitisInfections and infestations0/170/970/474/59
DiarrhoeaGastrointestinal disorders0/171/973/471/59
Haemolytic anaemiaBlood and lymphatic system disorders1/170/970/470/59
Abdominal painGastrointestinal disorders1/172/970/470/59
Most frequent other events
Showing 10 of 117
Most frequent other events
EventEltrombopag, Part 1 SubjectsEltrombopag, Part 2 Plus 1 Day From Part 2 SubjectsPlacebo, Part 2 Plus 1 Day From Part 2 SubjectsEltrombopag, Part 3 Plus 30 Days From Part 2 Subjects
PetechiaeSkin and subcutaneous tissue disorders6/1741/9711/478/59
EpistaxisRespiratory, thoracic and mediastinal disorders5/1727/9711/4712/59
NauseaGastrointestinal disorders1/1713/978/4714/59
FatigueGeneral disorders1/1723/973/479/59
DiarrhoeaGastrointestinal disorders4/1720/975/4711/59
PyrexiaGeneral disorders4/1718/9710/4712/59
PneumoniaInfections and infestations4/173/971/472/59
HaematomaVascular disorders0/177/979/479/59
AnaemiaBlood and lymphatic system disorders3/178/972/472/59
ConstipationGastrointestinal disorders3/1712/970/477/59

Baseline characteristics

Part 3, 59 subjects from Part 2 entered Part 3 (23 of 47 subjects in the placebo group in Part 2 and 36 of 98 subjects in the eltrombopag group in Part 2). All subjects who entered Part 3 received treatment with eltrombopag. SOC was allowed as needed throughout the study. Subjects could receive disease-modifying therapy as needed.

Age, Continuous
Age, Continuous(Years)Part 1: EltrombopagPart 2: PlaceboPart 2: EltrombopagTotal
Mean71.5 ± 10.7870.6 ± 10.7272.3 ± 8.9471.8 ± 9.56
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: EltrombopagPart 2: PlaceboPart 2: EltrombopagTotal
Female7163255
Male103166107
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: EltrombopagPart 2: PlaceboPart 2: EltrombopagTotal
African American/African Heritage0011
Asian - East Asian Heritage35917
Asian - South East Asian Heritage0224
White - Arabic/North African Heritage0156
White - White/Caucasian/European Heritage143981134
08

Study locations

120 sites
  • Novartis Investigative Site
    Phoenix, Arizona 85016, United States
  • Novartis Investigative Site
    Hot Springs, Arkansas 71913, United States
  • Novartis Investigative Site
    Jonesboro, Arkansas 72401, United States
  • Novartis Investigative Site
    Los Angeles, California 90095, United States
  • Novartis Investigative Site
    Stanford, California 94305, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32256, United States
  • Novartis Investigative Site
    Orlando, Florida 32806, United States
  • Novartis Investigative Site
    West Palm Beach, Florida 33401, United States
  • Novartis Investigative Site
    Augusta, Georgia 30912, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21201, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02115, United States
  • Novartis Investigative Site
    Kansas City, Missouri 64128, United States
  • Novartis Investigative Site
    Hackensack, New Jersey 07601, United States
  • Novartis Investigative Site
    Voorhees, New Jersey 08043, United States
  • Novartis Investigative Site
    The Bronx, New York 10467, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19140, United States
  • Novartis Investigative Site
    Seattle, Washington 98108, United States
  • Novartis Investigative Site
    Milwaukee, Wisconsin 53226, United States
  • Novartis Investigative Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1431FWO, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires B1900AXI, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Buenos Aires, C1025ABH, Argentina
  • Novartis Investigative Site
    Ciudad Autónoma de Buenos Aires, 1405, Argentina
  • Novartis Investigative Site
    Ciudad Autónoma de Buenos Aires, 1405, Argentina
  • Novartis Investigative Site
    Antwerpen, 2060, Belgium
  • Novartis Investigative Site
    Brasschaat, 2930, Belgium
  • Novartis Investigative Site
    Brugge, 8000, Belgium
  • Novartis Investigative Site
    Bruxelles, 1000, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Yvoir, 5530, Belgium
  • Novartis Investigative Site
    Goiânia - GO, Goiás 74605-020, Brazil
  • Novartis Investigative Site
    Goiânia - GO, Goiás 74605-020, Brazil
  • Novartis Investigative Site
    Curitiba, Paraná 81520-060, Brazil
  • Novartis Investigative Site
    Curitiba, Paraná 81520-060, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • Novartis Investigative Site
    Barretos, São Paulo 14784-400, Brazil
  • Novartis Investigative Site
    Barretos, São Paulo 14784-400, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, 20211-030, Brazil
  • Novartis Investigative Site
    São Paulo, 01236030, Brazil
  • Novartis Investigative Site
    São Paulo, 01236030, Brazil
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3T 1E2, Canada
  • Novartis Investigative Site
    Brno, 625 00, Czechia
  • Novartis Investigative Site
    Praha 10, 100 34, Czechia
  • Novartis Investigative Site
    Praha 2, 128 08, Czechia
  • Novartis Investigative Site
    Praha, 128 20, Czechia
  • Novartis Investigative Site
    Mannheim, Baden-Wuerttemberg 68167, Germany
  • Novartis Investigative Site
    Stuttgart, Baden-Wuerttemberg 70199, Germany
  • Novartis Investigative Site
    Goettingen, Niedersachsen 37075, Germany
  • Novartis Investigative Site
    Duesseldorf, Nordrhein-Westfalen 40225, Germany
  • Novartis Investigative Site
    Koeln, Nordrhein-Westfalen 50937, Germany
  • Novartis Investigative Site
    Dresden, Sachsen 01307, Germany
  • Novartis Investigative Site
    Athens, 11527, Greece
  • Novartis Investigative Site
    Heraklion, Crete, 71201, Greece
  • Novartis Investigative Site
    Ioannina, 45 500, Greece
  • Novartis Investigative Site
    Thessaloniki, 57010, Greece
  • Novartis Investigative Site
    Chai Wan, Hong Kong
  • Novartis Investigative Site
    Shatin, New Territories, Hong Kong
  • Novartis Investigative Site
    Budapest, 1088, Hungary
  • Novartis Investigative Site
    Debrecen, 4012, Hungary
  • Novartis Investigative Site
    Kaposvár, 7400, Hungary
  • Novartis Investigative Site
    Kaposvár, 7400, Hungary
  • Novartis Investigative Site
    Szeged, 6720, Hungary
  • Novartis Investigative Site
    Cork, Ireland
  • Novartis Investigative Site
    Dublin, 7, Ireland
  • Novartis Investigative Site
    James Street, 8, Ireland
  • Novartis Investigative Site
    Limerick, Ireland
  • Novartis Investigative Site
    Tallaght, Dublin, 24, Ireland
  • Novartis Investigative Site
    Tullamore, Ireland
  • Novartis Investigative Site
    Beer-Sheva, 84101, Israel
  • Novartis Investigative Site
    Haifa, 31048, Israel
  • Novartis Investigative Site
    Haifa, 31096, Israel
  • Novartis Investigative Site
    Holon, 58100, Israel
  • Novartis Investigative Site
    Jerusalem, 91120, Israel
  • Novartis Investigative Site
    Petach-Tikva, 49100, Israel
  • Novartis Investigative Site
    Ramat Gan, 52621, Israel
  • Novartis Investigative Site
    Rehovot, 76100, Israel
  • Novartis Investigative Site
    Tel Aviv, 64239, Israel
  • Novartis Investigative Site
    Bologna, Emilia-Romagna 40138, Italy
  • Novartis Investigative Site
    Brescia, Lombardia 25123, Italy
  • Novartis Investigative Site
    Milano, Lombardia 20122, Italy
  • Novartis Investigative Site
    Milano, Lombardia 20162, Italy
  • Novartis Investigative Site
    Alessandria, Piemonte 15100, Italy
  • Novartis Investigative Site
    Firenze, Toscana 50134, Italy
  • Novartis Investigative Site
    Hwasun, 519-809, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 110-744, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 120-752, Korea, Republic of
  • Novartis Investigative Site
    Monterrey, Nuevo León 64460, Mexico
  • Novartis Investigative Site
    Monterrey, Nuevo León 64460, Mexico
  • Novartis Investigative Site
    Chihuahua, 31203, Mexico
  • Novartis Investigative Site
    Mexico City, CP 14080, Mexico
  • Novartis Investigative Site
    Oaxaca, 68000, Mexico
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Chorzow, 41-500, Poland
  • Novartis Investigative Site
    Torun, 87-100, Poland
  • Novartis Investigative Site
    Warszawa, 02-097, Poland
  • Novartis Investigative Site
    San Juan, 00927, Puerto Rico
  • Novartis Investigative Site
    Nizhniy Novgorod, 603126, Russian Federation
  • Novartis Investigative Site
    Petrozavodsk, 185019, Russian Federation

Showing the first 100 of 120 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, Brenner B, Denzlinger C, Rossi G, Nagler A, Garcia-Delgado R, Portella MSO, Zhu Z, Selleslag D. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018 Jan;5(1):e34-e43. doi: 10.1016/S2352-3026(17)30228-4. Epub 2017 Dec 11. PubMed 29241762 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Mar 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2011
First posted
Sep 26, 2011
Start
Sep 2011
Primary completionActual
Mar 2015
CompletionActual
Dec 2015
Results first posted
Jun 14, 2016
Last update
Jun 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01440374
Responsible party
Sponsor
First posted
Sep 26, 2011
Start date
Sep 2011
Primary completion
Mar 2015
Completion
Dec 2015
Results posted
Jun 14, 2016
Last update
Jun 5, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion